Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 8,400 shares, a growth of 110.0% from the October 15th total of 4,000 shares. Based on an average trading volume of 29,500 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.0% of the company’s shares are sold short.

Institutional Investors Weigh In On Barinthus Biotherapeutics

Several large investors have recently bought and sold shares of the business. Alphabet Inc. bought a new stake in Barinthus Biotherapeutics in the 2nd quarter worth about $2,119,000. Catalina Capital Group LLC bought a new stake in Barinthus Biotherapeutics in the 2nd quarter worth about $25,000. Ipswich Investment Management Co. Inc. bought a new stake in Barinthus Biotherapeutics in the 2nd quarter worth about $32,000. M&G Plc bought a new stake in Barinthus Biotherapeutics in the 2nd quarter worth about $7,276,000. Finally, BlueCrest Capital Management Ltd bought a new stake in shares of Barinthus Biotherapeutics during the 1st quarter valued at about $1,292,000. 25.20% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Alliance Global Partners dropped their price target on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Barinthus Biotherapeutics in a research note on Friday, November 8th.

Barinthus Biotherapeutics Trading Down 3.6 %

Barinthus Biotherapeutics stock traded down $0.05 on Thursday, hitting $1.35. 18,768 shares of the stock traded hands, compared to its average volume of 23,819. The business’s fifty day simple moving average is $1.29 and its 200 day simple moving average is $1.54. The firm has a market cap of $54.31 million, a P/E ratio of -0.94 and a beta of -0.59. Barinthus Biotherapeutics has a 1 year low of $1.11 and a 1 year high of $4.16.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.23. The company had revenue of $14.97 million during the quarter. During the same period in the previous year, the company posted ($0.37) earnings per share. As a group, analysts predict that Barinthus Biotherapeutics will post -1.52 earnings per share for the current year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.